Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TAF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TAF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TAF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TAF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
GO:0009303 | Liver | HCC | rRNA transcription | 25/7958 | 34/18723 | 2.42e-04 | 1.81e-03 | 25 |
GO:00439231 | Liver | HCC | positive regulation by host of viral transcription | 14/7958 | 16/18723 | 2.73e-04 | 1.98e-03 | 14 |
GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
GO:001810711 | Liver | HCC | peptidyl-threonine phosphorylation | 68/7958 | 116/18723 | 3.31e-04 | 2.33e-03 | 68 |
GO:190336321 | Liver | HCC | negative regulation of cellular protein catabolic process | 47/7958 | 75/18723 | 3.36e-04 | 2.35e-03 | 47 |
GO:0006360 | Liver | HCC | transcription by RNA polymerase I | 36/7958 | 55/18723 | 4.94e-04 | 3.23e-03 | 36 |
GO:003090121 | Liver | HCC | midbrain development | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
GO:00165791 | Liver | HCC | protein deubiquitination | 78/7958 | 139/18723 | 8.13e-04 | 4.87e-03 | 78 |
GO:001821011 | Liver | HCC | peptidyl-threonine modification | 71/7958 | 125/18723 | 8.68e-04 | 5.14e-03 | 71 |
GO:00708971 | Liver | HCC | transcription preinitiation complex assembly | 25/7958 | 36/18723 | 9.87e-04 | 5.71e-03 | 25 |
GO:1902806 | Liver | HCC | regulation of cell cycle G1/S phase transition | 91/7958 | 168/18723 | 1.47e-03 | 7.79e-03 | 91 |
GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
GO:190236921 | Liver | HCC | negative regulation of RNA catabolic process | 45/7958 | 75/18723 | 1.67e-03 | 8.73e-03 | 45 |
GO:0016578 | Liver | HCC | histone deubiquitination | 17/7958 | 23/18723 | 2.28e-03 | 1.13e-02 | 17 |
GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
GO:0043966 | Liver | HCC | histone H3 acetylation | 37/7958 | 61/18723 | 3.21e-03 | 1.48e-02 | 37 |
GO:004348921 | Liver | HCC | RNA stabilization | 39/7958 | 65/18723 | 3.31e-03 | 1.51e-02 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAF1 | SNV | Missense_Mutation | novel | c.3409N>A | p.Gln1137Lys | p.Q1137K | P21675 | protein_coding | deleterious(0.04) | probably_damaging(0.991) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
TAF1 | SNV | Missense_Mutation | novel | c.4912G>A | p.Asp1638Asn | p.D1638N | P21675 | protein_coding | tolerated(1) | benign(0.092) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.5638N>A | p.Glu1880Lys | p.E1880K | P21675 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TAF1 | SNV | Missense_Mutation | novel | c.85N>A | p.Asp29Asn | p.D29N | P21675 | protein_coding | tolerated_low_confidence(0.1) | benign(0.124) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
TAF1 | SNV | Missense_Mutation | novel | c.4675N>T | p.Pro1559Ser | p.P1559S | P21675 | protein_coding | deleterious(0.01) | possibly_damaging(0.752) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
TAF1 | SNV | Missense_Mutation | | c.1679G>T | p.Arg560Leu | p.R560L | P21675 | protein_coding | deleterious(0) | benign(0.44) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.4174C>T | p.His1392Tyr | p.H1392Y | P21675 | protein_coding | tolerated(0.17) | benign(0.021) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.2195N>G | p.Asp732Gly | p.D732G | P21675 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TAF1 | SNV | Missense_Mutation | rs760338471 | c.2698A>G | p.Met900Val | p.M900V | P21675 | protein_coding | deleterious(0.03) | benign(0.049) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
TAF1 | SNV | Missense_Mutation | | c.1816G>A | p.Gly606Arg | p.G606R | P21675 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD |